Fig. 1

Stable UPDRS Part II and III scores are maintained during therapy. a UPDRS, Part II raw scores (mean ± SD) grouped by time of treatment for all subjects. b UPDRS Part III raw scores (mean ± SD) grouped by time of treatment for all subjects. c Change from baseline UPDRS Part II scores grouped by time of treatment for all subjects (mean ± SD). d Change from baseline UPDRS Part III scores grouped by time of treatment for all subjects (mean ± SD). Blue nodes indicate baseline evaluations. Blue dashed line indicates baseline average. Green nodes indicate “on” sargramostim treatment and red nodes indicate drug cessation. Differences in means (± SD) for each dependent variable grouped by time on treatment were determined by one-way ANOVA (P values annotated) and P values for multiple comparisons with baseline were adjusted with Dunnett's post-hoc test (^a) and by false discovery rate (FDR) by the method of Benjamini, Krieger and Yekutieli [36] (*) where P ≤ 0.05. e Correlation analyses of UPDRS Part II and UPDRS Part III scores. Regression band is indicated by dashed lines that encompass the 95% confidence intervals (red) and 95% prediction values (blue). Correlation was determined using Pearson product-moment correlation coefficients, P values determined for correlation coefficients greater than 0.25, and best-fit lines were determined using linear regression. The Pearson r and P values are displayed on the graph. Data are depicted as scatter plots using the raw UPDRS Parts II and III scores